Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

100%

3 of 3 completed trials have results

Key Signals

1 recruiting3 with results

Enrollment Performance

Analytics

Phase 2
5(100.0%)
5Total
Phase 2(5)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT06936566Phase 2Recruiting

MAGIC Ruxolitinib for aGVHD

Role: lead

NCT05090384Phase 2Active Not Recruiting

Pediatric GVHD Low Risk Steroid Taper Trial

Role: lead

NCT03846479Phase 2Completed

Itacitinib for Low Risk GVHD

Role: lead

NCT02133924Phase 2Completed

Multicenter Study Of Natalizumab Plus Standard Steroid Treatment For High Risk Acute Graft-Versus-Host Disease

Role: lead

NCT03459040Phase 2Completed

A Proof of Concept Pilot Trial of Alpha-1-Antitrypsin for Pre-Emption Of Steroid-Refractory Acute GVHD

Role: lead

All 5 trials loaded